 "Biocon likely to channelise investments towards non-insulin biologics")
Biocon’s revenue growth, at just 3 per cent for the March quarter (Q4), as compared to 13-30 per cent in the first three quarters of FY20, was largely because of the Covid-19-led supply disruption. The biologics segment (biosimilars), which has driven Biocon’s performance for seven straight quarters, declined 21 per cent year-on-year (YoY) in Q4 as the supply scheduled for the end of the quarter could not be completed. For the full year, however, biologics (30 per cent of revenues) still grew by 29 per cent over the previous year.
Christiane Hamacher, CEO & managing director, Biocon Biologics, said this was
